Global RNA Analysis / Transcriptomics Market to Reach US$10.5 Billion by the Year 2026

·23 min read

Abstract: Global RNA Analysis / Transcriptomics Market to Reach US$10. 5 Billion by the Year 2026 . Transcriptomics is the study of the RNA transcripts set produced by the organism`s genome.

New York, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global RNA Analysis / Transcriptomics Industry" - https://www.reportlinker.com/p06219553/?utm_source=GNW
Transcriptome analysis enables researchers to understand DNA`s sequence as well as its functioning. The gene expression patterns` increased demand for specific genes, various assay technologies, quantification of multiplexed RNA, increased requirement for genetic testing and personalized medicine, rise in genetic variation and genetic mutation incidences boost the transcriptomics technologies market demand. Additionally, continuous technological developments in products increased commercialization, and increasing disease cases such as hepatitis B, diabetes, and cancer, too, propel the transcriptomics technologies market growth. Pharmaceutical and biotechnology companies` R&D funding, increased demand for compact and reliable products, too, are the other key factors anticipated to drive market growth. Innovations and new product launches are also projected to fuel the growth over the analysis period. For instance, NuGEN Technologies, Inc.`s Trio RNA-Seq, which provides a highly sensitive end-to-end transcriptomics solution, is ideal for use in low abundance transcripts applications. The innovative Trio RNA-Seq technique integrates three powerful technologies, including single primer isothermal amplification (SPIA); AnyDeplete, for use in high sensitivity ribonucleic acid (RNA) analysis; and DimerFree.

Amid the COVID-19 crisis, the global market for RNA Analysis / Transcriptomics estimated at US$4.7 Billion in the year 2020, is projected to reach a revised size of US$10.5 Billion by 2026, growing at a CAGR of 14.1% over the analysis period. Reagents / Consumables, one of the segments analyzed in the report, is projected to grow at a 15.4% CAGR to reach US$5.9 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Instruments segment is readjusted to a revised 12.5% CAGR for the next 7-year period. This segment currently accounts for a 30.1% share of the global RNA Analysis / Transcriptomics market.

The U.S. Market is Estimated at $2.2 Billion in 2021, While China is Forecast to Reach $891.5 Million by 2026

The RNA Analysis / Transcriptomics market in the U.S. is estimated at US$2.2 Billion in the year 2021. The country currently accounts for a 39.34% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$891.5 Million in the year 2026 trailing a CAGR of 15.6% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.9% and 14.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.8% CAGR while Rest of European market (as defined in the study) will reach US$1 Billion by the end of the analysis period. North America represents the most dominant region because of the presence of a large number of biotech companies having well-established infrastructure and state-of-the-art technological platforms. Growing opportunities, increasing healthcare expenditure, and the introduction of government initiatives are the other factors driving market growth. Additionally, the sustained increase in transcriptomics-related research and development investments by the private sector is enabling the regional market players to develop targeted therapeutics.

Services Segment to Reach $2 Billion by 2026

In the global Services segment, USA, Canada, Japan, China and Europe will drive the 14.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$744.8 Million in the year 2020 will reach a projected size of US$1.9 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$130.8 Million by the year 2026.


Select Competitors (Total 44 Featured)

  • Agilent Technologies, Inc.

  • Bio-Rad Laboratories, Inc.

  • CD Genomics

  • F. Hoffmann-La Roche Ltd.

  • GenXPro GmbH

  • Illumina, Inc.

  • LC Sciences

  • Merck KGaA

  • Qiagen N.V.

  • Sequentia Biotech SL

  • Thermo Fisher Scientific Inc.




Read the full report: https://www.reportlinker.com/p06219553/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
RNA-Seq Technology
A Prelude to Transcriptomics Technologies
Impact of Covid-19 and a Looming Global Recession
2020 Marked as a Year of Disruption & Transformation
As the Race between the Virus & Vaccines Intensifies, Where is
the World Economy Headed in 2021
EXHIBIT 1: World Economic Growth Projections (Real GDP, Annual %
Change) for 2020 through 2022
COVID-19 Impact on Global Transcriptomics Technologies Market
Growth Prospects and Outlook
Global Transcriptomics Technologies Market Witnesses Rapid Growth
Market Outlook
Segmentation by Technology
Application-based Analysis
Geography-based Analysis
North America Leads the Market
Competition
Recent Market Activity

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS
Growing Demand for Personalized Medicine to Drive Market Demand
EXHIBIT 2: Global Personalized Medicine Market: Revenues in US$
Million for the Years 2019 and 2024
Transcriptomics Application in Disease and Diagnostic Profiling
Increasing PCR applications in Biotechnology Sector
The Growing Role of Transcriptomics in Oncology
EXHIBIT 3: Global Cancer Incidence: Number of New Cancer Cases
in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
EXHIBIT 4: Global Number of New Cancer Cases and Cancer-related
Deaths by Cancer Site for 2018
EXHIBIT 5: Number of New Cancer Cases and Deaths (in Million)
by Region for 2018
Single-cell RNA-seq Technologies Witness Steady Growth
Growth of Long-Read Transcriptome Sequencing
Gene Expression Microarray Technology Gains Ground
Conventional Microarrays
Latest Microarrays
Microfluidics-based Droplet Technologies Witness Growth
inDrops Approach Exhibits Growth
Spatial Transcriptomics Market Witnesses Significant Growth
Next Generation Sequencing Offers Increased Accuracy for
Transcriptomics Activity
Select NGS Platforms Available in the Market
Single-cell NGS Witnesses Rapid Growth
RNA Sequencing Registers Significant Growth
Blood Transcriptome Sequencing for Identifying Rare-Disease Genes
Liquid Biopsy
Plant Gene Expression
Nanopore RNA Sequencing
3?RNA Sequencing
Specific Targeted Sequencing
NanoString Technology - A Proprietary Transcriptomics Technology
Technological Advancements and Innovations
Sci-Plex - A New Technique to Profile Gene Expression within
Single Cells
Introduction of Oxford Nanopore?s Innovative Portable Sequencer
for Sequencing Long Reads and RNA Molecules Improves
Transcriptomic Analysis
Aging Demographics Present Opportunities for Transcriptomics
Technologies
EXHIBIT 6: Expanding Elderly Population Worldwide: Breakdown of
Number of People Aged 65+ Years in Million by Geographic
Region for the Years 2019 and 2030
EXHIBIT 7: Expanding Elderly Population Worldwide: Breakdown of
Number of People Aged 65+ Years in Million by Geographic
Region for the Years 2019 and 2030
Transcriptomics Assume Critical Importance amid Growing
Prevalence of Chronic Diseases
EXHIBIT 8: Rising Diabetes Prevalence Presents Opportunity for
Cell Surface Markers: Number of Adults (20-79) with Diabetes
(in Millions) by Region for 2017 and 2045
EXHIBIT 9: Fatalities by Heart Conditions: Estimated Percentage
Breakdown for Cardiovascular Disease, Ischemic Heart Disease,
Stroke, and Others

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for RNA Analysis /
Transcriptomics by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for RNA Analysis /
Transcriptomics by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2015 through 2019 and % CAGR

Table 3: World 12-Year Perspective for RNA Analysis /
Transcriptomics by Geographic Region - Percentage Breakdown of
Value Revenues for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets for Years 2015, 2021 &
2027

Table 4: World Current & Future Analysis for Reagents /
Consumables by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2020
through 2027 and % CAGR

Table 5: World Historic Review for Reagents / Consumables by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2015 through 2019
and % CAGR

Table 6: World 12-Year Perspective for Reagents / Consumables
by Geographic Region - Percentage Breakdown of Value Revenues
for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2015, 2021 & 2027

Table 7: World Current & Future Analysis for Instruments by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2020 through 2027
and % CAGR

Table 8: World Historic Review for Instruments by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Revenues
in US$ Thousand for Years 2015 through 2019 and % CAGR

Table 9: World 12-Year Perspective for Instruments by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2015, 2021 & 2027

Table 10: World Current & Future Analysis for Services by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2020 through 2027
and % CAGR

Table 11: World Historic Review for Services by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Revenues
in US$ Thousand for Years 2015 through 2019 and % CAGR

Table 12: World 12-Year Perspective for Services by Geographic
Region - Percentage Breakdown of Value Revenues for USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
for Years 2015, 2021 & 2027

Table 13: World Current & Future Analysis for Software by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2020 through 2027
and % CAGR

Table 14: World Historic Review for Software by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Revenues
in US$ Thousand for Years 2015 through 2019 and % CAGR

Table 15: World 12-Year Perspective for Software by Geographic
Region - Percentage Breakdown of Value Revenues for USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
for Years 2015, 2021 & 2027

Table 16: World Current & Future Analysis for Polymerase Chain
Reaction by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2020
through 2027 and % CAGR

Table 17: World Historic Review for Polymerase Chain Reaction
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2015 through 2019
and % CAGR

Table 18: World 12-Year Perspective for Polymerase Chain
Reaction by Geographic Region - Percentage Breakdown of Value
Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2015, 2021 & 2027

Table 19: World Current & Future Analysis for Sequencing by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2020 through 2027
and % CAGR

Table 20: World Historic Review for Sequencing by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Revenues
in US$ Thousand for Years 2015 through 2019 and % CAGR

Table 21: World 12-Year Perspective for Sequencing by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2015, 2021 & 2027

Table 22: World Current & Future Analysis for Microarrays by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2020 through 2027
and % CAGR

Table 23: World Historic Review for Microarrays by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Revenues
in US$ Thousand for Years 2015 through 2019 and % CAGR

Table 24: World 12-Year Perspective for Microarrays by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2015, 2021 & 2027

Table 25: World Current & Future Analysis for RNA Interference
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2020 through 2027
and % CAGR

Table 26: World Historic Review for RNA Interference by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2015 through 2019
and % CAGR

Table 27: World 12-Year Perspective for RNA Interference by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2015, 2021 & 2027

Table 28: World Current & Future Analysis for Drug Discovery by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2020 through 2027
and % CAGR

Table 29: World Historic Review for Drug Discovery by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2015 through 2019
and % CAGR

Table 30: World 12-Year Perspective for Drug Discovery by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2015, 2021 & 2027

Table 31: World Current & Future Analysis for Toxicogenomics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2020 through 2027
and % CAGR

Table 32: World Historic Review for Toxicogenomics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2015 through 2019
and % CAGR

Table 33: World 12-Year Perspective for Toxicogenomics by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2015, 2021 & 2027

Table 34: World Current & Future Analysis for Clinical
Diagnostics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2020
through 2027 and % CAGR

Table 35: World Historic Review for Clinical Diagnostics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2015 through 2019
and % CAGR

Table 36: World 12-Year Perspective for Clinical Diagnostics by
Geographic Region - Percentage Breakdown of Value Revenues for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2015, 2021 & 2027

Table 37: World Current & Future Analysis for Comparative
Transcriptomics by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2020 through 2027 and % CAGR

Table 38: World Historic Review for Comparative Transcriptomics
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Revenues in US$ Thousand for Years 2015 through 2019
and % CAGR

Table 39: World 12-Year Perspective for Comparative
Transcriptomics by Geographic Region - Percentage Breakdown of
Value Revenues for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2015, 2021 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 40: USA Current & Future Analysis for RNA Analysis /
Transcriptomics by Product - Reagents / Consumables,
Instruments, Services and Software - Independent Analysis of
Annual Revenues in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 41: USA Historic Review for RNA Analysis /
Transcriptomics by Product - Reagents / Consumables,
Instruments, Services and Software Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2015
through 2019 and % CAGR

Table 42: USA 12-Year Perspective for RNA Analysis /
Transcriptomics by Product - Percentage Breakdown of Value
Revenues for Reagents / Consumables, Instruments, Services and
Software for the Years 2015, 2021 & 2027

Table 43: USA Current & Future Analysis for RNA Analysis /
Transcriptomics by Technology - Polymerase Chain Reaction,
Sequencing, Microarrays and RNA Interference - Independent
Analysis of Annual Revenues in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 44: USA Historic Review for RNA Analysis /
Transcriptomics by Technology - Polymerase Chain Reaction,
Sequencing, Microarrays and RNA Interference Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2015 through 2019 and % CAGR

Table 45: USA 12-Year Perspective for RNA Analysis /
Transcriptomics by Technology - Percentage Breakdown of Value
Revenues for Polymerase Chain Reaction, Sequencing, Microarrays
and RNA Interference for the Years 2015, 2021 & 2027

Table 46: USA Current & Future Analysis for RNA Analysis /
Transcriptomics by Application - Drug Discovery,
Toxicogenomics, Clinical Diagnostics and Comparative
Transcriptomics - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 47: USA Historic Review for RNA Analysis /
Transcriptomics by Application - Drug Discovery,
Toxicogenomics, Clinical Diagnostics and Comparative
Transcriptomics Markets - Independent Analysis of Annual
Revenues in US$ Thousand for Years 2015 through 2019 and % CAGR

Table 48: USA 12-Year Perspective for RNA Analysis /
Transcriptomics by Application - Percentage Breakdown of Value
Revenues for Drug Discovery, Toxicogenomics, Clinical
Diagnostics and Comparative Transcriptomics for the Years 2015,
2021 & 2027

CANADA
Table 49: Canada Current & Future Analysis for RNA Analysis /
Transcriptomics by Product - Reagents / Consumables,
Instruments, Services and Software - Independent Analysis of
Annual Revenues in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 50: Canada Historic Review for RNA Analysis /
Transcriptomics by Product - Reagents / Consumables,
Instruments, Services and Software Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2015
through 2019 and % CAGR

Table 51: Canada 12-Year Perspective for RNA Analysis /
Transcriptomics by Product - Percentage Breakdown of Value
Revenues for Reagents / Consumables, Instruments, Services and
Software for the Years 2015, 2021 & 2027

Table 52: Canada Current & Future Analysis for RNA Analysis /
Transcriptomics by Technology - Polymerase Chain Reaction,
Sequencing, Microarrays and RNA Interference - Independent
Analysis of Annual Revenues in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 53: Canada Historic Review for RNA Analysis /
Transcriptomics by Technology - Polymerase Chain Reaction,
Sequencing, Microarrays and RNA Interference Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2015 through 2019 and % CAGR

Table 54: Canada 12-Year Perspective for RNA Analysis /
Transcriptomics by Technology - Percentage Breakdown of Value
Revenues for Polymerase Chain Reaction, Sequencing, Microarrays
and RNA Interference for the Years 2015, 2021 & 2027

Table 55: Canada Current & Future Analysis for RNA Analysis /
Transcriptomics by Application - Drug Discovery,
Toxicogenomics, Clinical Diagnostics and Comparative
Transcriptomics - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 56: Canada Historic Review for RNA Analysis /
Transcriptomics by Application - Drug Discovery,
Toxicogenomics, Clinical Diagnostics and Comparative
Transcriptomics Markets - Independent Analysis of Annual
Revenues in US$ Thousand for Years 2015 through 2019 and % CAGR

Table 57: Canada 12-Year Perspective for RNA Analysis /
Transcriptomics by Application - Percentage Breakdown of Value
Revenues for Drug Discovery, Toxicogenomics, Clinical
Diagnostics and Comparative Transcriptomics for the Years 2015,
2021 & 2027

JAPAN
Table 58: Japan Current & Future Analysis for RNA Analysis /
Transcriptomics by Product - Reagents / Consumables,
Instruments, Services and Software - Independent Analysis of
Annual Revenues in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 59: Japan Historic Review for RNA Analysis /
Transcriptomics by Product - Reagents / Consumables,
Instruments, Services and Software Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2015
through 2019 and % CAGR

Table 60: Japan 12-Year Perspective for RNA Analysis /
Transcriptomics by Product - Percentage Breakdown of Value
Revenues for Reagents / Consumables, Instruments, Services and
Software for the Years 2015, 2021 & 2027

Table 61: Japan Current & Future Analysis for RNA Analysis /
Transcriptomics by Technology - Polymerase Chain Reaction,
Sequencing, Microarrays and RNA Interference - Independent
Analysis of Annual Revenues in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 62: Japan Historic Review for RNA Analysis /
Transcriptomics by Technology - Polymerase Chain Reaction,
Sequencing, Microarrays and RNA Interference Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2015 through 2019 and % CAGR

Table 63: Japan 12-Year Perspective for RNA Analysis /
Transcriptomics by Technology - Percentage Breakdown of Value
Revenues for Polymerase Chain Reaction, Sequencing, Microarrays
and RNA Interference for the Years 2015, 2021 & 2027

Table 64: Japan Current & Future Analysis for RNA Analysis /
Transcriptomics by Application - Drug Discovery,
Toxicogenomics, Clinical Diagnostics and Comparative
Transcriptomics - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 65: Japan Historic Review for RNA Analysis /
Transcriptomics by Application - Drug Discovery,
Toxicogenomics, Clinical Diagnostics and Comparative
Transcriptomics Markets - Independent Analysis of Annual
Revenues in US$ Thousand for Years 2015 through 2019 and % CAGR

Table 66: Japan 12-Year Perspective for RNA Analysis /
Transcriptomics by Application - Percentage Breakdown of Value
Revenues for Drug Discovery, Toxicogenomics, Clinical
Diagnostics and Comparative Transcriptomics for the Years 2015,
2021 & 2027

CHINA
Table 67: China Current & Future Analysis for RNA Analysis /
Transcriptomics by Product - Reagents / Consumables,
Instruments, Services and Software - Independent Analysis of
Annual Revenues in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 68: China Historic Review for RNA Analysis /
Transcriptomics by Product - Reagents / Consumables,
Instruments, Services and Software Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2015
through 2019 and % CAGR

Table 69: China 12-Year Perspective for RNA Analysis /
Transcriptomics by Product - Percentage Breakdown of Value
Revenues for Reagents / Consumables, Instruments, Services and
Software for the Years 2015, 2021 & 2027

Table 70: China Current & Future Analysis for RNA Analysis /
Transcriptomics by Technology - Polymerase Chain Reaction,
Sequencing, Microarrays and RNA Interference - Independent
Analysis of Annual Revenues in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 71: China Historic Review for RNA Analysis /
Transcriptomics by Technology - Polymerase Chain Reaction,
Sequencing, Microarrays and RNA Interference Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2015 through 2019 and % CAGR

Table 72: China 12-Year Perspective for RNA Analysis /
Transcriptomics by Technology - Percentage Breakdown of Value
Revenues for Polymerase Chain Reaction, Sequencing, Microarrays
and RNA Interference for the Years 2015, 2021 & 2027

Table 73: China Current & Future Analysis for RNA Analysis /
Transcriptomics by Application - Drug Discovery,
Toxicogenomics, Clinical Diagnostics and Comparative
Transcriptomics - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 74: China Historic Review for RNA Analysis /
Transcriptomics by Application - Drug Discovery,
Toxicogenomics, Clinical Diagnostics and Comparative
Transcriptomics Markets - Independent Analysis of Annual
Revenues in US$ Thousand for Years 2015 through 2019 and % CAGR

Table 75: China 12-Year Perspective for RNA Analysis /
Transcriptomics by Application - Percentage Breakdown of Value
Revenues for Drug Discovery, Toxicogenomics, Clinical
Diagnostics and Comparative Transcriptomics for the Years 2015,
2021 & 2027

EUROPE
Table 76: Europe Current & Future Analysis for RNA Analysis /
Transcriptomics by Geographic Region - France, Germany, Italy,
UK and Rest of Europe Markets - Independent Analysis of Annual
Revenues in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 77: Europe Historic Review for RNA Analysis /
Transcriptomics by Geographic Region - France, Germany, Italy,
UK and Rest of Europe Markets - Independent Analysis of Annual
Revenues in US$ Thousand for Years 2015 through 2019 and % CAGR

Table 78: Europe 12-Year Perspective for RNA Analysis /
Transcriptomics by Geographic Region - Percentage Breakdown of
Value Revenues for France, Germany, Italy, UK and Rest of
Europe Markets for Years 2015, 2021 & 2027

Table 79: Europe Current & Future Analysis for RNA Analysis /
Transcriptomics by Product - Reagents / Consumables,
Instruments, Services and Software - Independent Analysis of
Annual Revenues in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 80: Europe Historic Review for RNA Analysis /
Transcriptomics by Product - Reagents / Consumables,
Instruments, Services and Software Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2015
through 2019 and % CAGR

Table 81: Europe 12-Year Perspective for RNA Analysis /
Transcriptomics by Product - Percentage Breakdown of Value
Revenues for Reagents / Consumables, Instruments, Services and
Software for the Years 2015, 2021 & 2027

Table 82: Europe Current & Future Analysis for RNA Analysis /
Transcriptomics by Technology - Polymerase Chain Reaction,
Sequencing, Microarrays and RNA Interference - Independent
Analysis of Annual Revenues in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 83: Europe Historic Review for RNA Analysis /
Transcriptomics by Technology - Polymerase Chain Reaction,
Sequencing, Microarrays and RNA Interference Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2015 through 2019 and % CAGR

Table 84: Europe 12-Year Perspective for RNA Analysis /
Transcriptomics by Technology - Percentage Breakdown of Value
Revenues for Polymerase Chain Reaction, Sequencing, Microarrays
and RNA Interference for the Years 2015, 2021 & 2027

Table 85: Europe Current & Future Analysis for RNA Analysis /
Transcriptomics by Application - Drug Discovery,
Toxicogenomics, Clinical Diagnostics and Comparative
Transcriptomics - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 86: Europe Historic Review for RNA Analysis /
Transcriptomics by Application - Drug Discovery,
Toxicogenomics, Clinical Diagnostics and Comparative
Transcriptomics Markets - Independent Analysis of Annual
Revenues in US$ Thousand for Years 2015 through 2019 and % CAGR

Table 87: Europe 12-Year Perspective for RNA Analysis /
Transcriptomics by Application - Percentage Breakdown of Value
Revenues for Drug Discovery, Toxicogenomics, Clinical
Diagnostics and Comparative Transcriptomics for the Years 2015,
2021 & 2027

FRANCE
Table 88: France Current & Future Analysis for RNA Analysis /
Transcriptomics by Product - Reagents / Consumables,
Instruments, Services and Software - Independent Analysis of
Annual Revenues in US$ Thousand for the Years 2020 through 2027
and % CAGR

Table 89: France Historic Review for RNA Analysis /
Transcriptomics by Product - Reagents / Consumables,
Instruments, Services and Software Markets - Independent
Analysis of Annual Revenues in US$ Thousand for Years 2015
through 2019 and % CAGR

Table 90: France 12-Year Perspective for RNA Analysis /
Transcriptomics by Product - Percentage Breakdown of Value
Revenues for Reagents / Consumables, Instruments, Services and
Software for the Years 2015, 2021 & 2027

Table 91: France Current & Future Analysis for RNA Analysis /
Transcriptomics by Technology - Polymerase Chain Reaction,
Sequencing, Microarrays and RNA Interference - Independent
Analysis of Annual Revenues in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 92: France Historic Review for RNA Analysis /
Transcriptomics by Technology - Polymerase Chain Reaction,
Sequencing, Microarrays and RNA Interference Markets -
Independent Analysis of Annual Revenues in US$ Thousand for
Years 2015 through 2019 and % CAGR

Table 93: France 12-Year Perspective for RNA Analysis /
Transcriptomics by Technology - Percentage Breakdown of Value
Revenues for Polymerase Chain Reaction, Sequencing, Microarrays
and RNA Interference for the Years 2015, 2021 & 2027

Table 94: France Current & Future Analysis for RNA Analysis /
Transcriptomics by Application - Drug Discovery,
Toxicogenomics, Clinical Diagnostics and Comparative
Transcriptomics - Independent Analysis of Annual Revenues in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 95: France Historic Review for RNA Analysis /
Transcriptomics by Application - Drug Discovery,
Toxicogenomics, Clinical Diagnostics and Comparative
Transcriptomics Markets - Independent Analysis of Annual
Revenues in US$ Thousand for Years 2015 through 2019 and % CAGR

Table 96: France 12-Year Perspective for RNA Analysis /
Transcriptomics by Application - Percentage Breakdown of Value
Revenues for Drug Discovery, Toxicogenomics, Clinical
Diagnostics and Comparative Transcriptomics for the Years 2015,
2021 & 2027

GERMANY
Table 97: Germany Current & Future Analysis for RNA Analysis /
Transcriptomics by Product - Reagents / Consumables,
Instruments, Services and Software - Independent Analysis of
Annual Revenues in US$ Thousand for the Years 2020 through 2027

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06219553/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001